http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108778291-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B40-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2017-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108778291-B |
| titleOfInvention | Compositions and libraries comprising recombinant T cell receptors and methods of using recombinant T cell receptors |
| abstract | Recombinant polynucleotides are provided, including those encoding cells derived from novel AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T and PB13.2T cell receptors as embodiments of the present invention. An expression vector for the alpha chain and/or beta chain of the TCR of the amino acid sequence of any one of the TCRs. Cells comprising polynucleotides are provided, as well as libraries of recombinant polynucleotides and expression vectors. Methods are provided comprising administering to an individual modified human T cells expressing a novel recombinant TCR. The method is for preventing and/or treating an individual diagnosed with, suspected of having, or at risk of developing or recurring cancer, wherein the cancer comprises LAGE-expressing NY-ESO-1 and/or its highly homologous 1 antigen of cancer cells. |
| priorityDate | 2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 396.